| Reaction Details |
|---|
 | Report a problem with these data |
| Target | G2/mitotic-specific cyclin-B1 |
|---|
| Ligand | BDBM43767 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | Counterscreen assay for inhibitors of Wee1 degradation: dose response cell-based assay to identify inhibitors of cyclin B degradation |
|---|
| EC50 | >49750±n/a nM |
|---|
| Citation |  PubChem, PC Counterscreen assay for inhibitors of Wee1 degradation: dose response cell-based assay to identify inhibitors of cyclin B degradation PubChem Bioassay(2008)[AID] |
|---|
| More Info.: | Get all data from this article, Solution Info, Assay Method |
|---|
| |
| G2/mitotic-specific cyclin-B1 |
|---|
| Name: | G2/mitotic-specific cyclin-B1 |
|---|
| Synonyms: | CCNB | CCNB1 | CCNB1_HUMAN |
|---|
| Type: | Enzyme Subunit |
|---|
| Mol. Mass.: | 48340.95 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P14635 |
|---|
| Residue: | 433 |
|---|
| Sequence: | MALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRTALGDIGNKVSEQLQAKM
PMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPI
LVDTASPSPMETSGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIYAYLRQ
LEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVP
KKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRP
LPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDNGE
WTPTLQHYLSYTEESLLPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQLNS
ALVQDLAKAVAKV
|
|
|
|---|
| BDBM43767 |
|---|
| n/a |
|---|
| Name | BDBM43767 |
|---|
| Synonyms: | 2-[4-(4-fluorobenzoyl)phenoxy]-N-(4-fluorobenzyl)acetamide | 2-[4-(4-fluorobenzoyl)phenoxy]-N-[(4-fluorophenyl)methyl]acetamide | 2-[4-(4-fluorophenyl)carbonylphenoxy]-N-[(4-fluorophenyl)methyl]ethanamide | MLS000388774 | N-[(4-fluorophenyl)methyl]-2-[4-[(4-fluorophenyl)-oxomethyl]phenoxy]acetamide | SMR000254947 | cid_2564901 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C22H17F2NO3 |
|---|
| Mol. Mass. | 381.3721 |
|---|
| SMILES | Fc1ccc(CNC(=O)COc2ccc(cc2)C(=O)c2ccc(F)cc2)cc1 |
|---|
| Structure | 
|
|---|
Search and Browse
